<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Moderate to severe hypertensive retinopathy and hypertensive encephalopathy in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J Elliott, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph Varon, MD, FACP, FCCP, FCCM, FRSM</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George L Bakris, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William B White, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">DEFINITIONS AND TERMINOLOGY</span><span class="headingEndMark"> — </span>Hypertensive emergencies are acute, life-threatening conditions resulting from markedly increased blood pressure (BP), generally ≥180/120 mmHg  (<a class="graphic graphic_table graphicRef54145" href="/z/d/graphic/54145.html" rel="external">table 1</a>), characterized by acute, ongoing target-organ damage [<a href="#rid1">1-5</a>]. In addition to the hypertensive emergencies that are discussed in detail elsewhere (see  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults"</a>), two less common clinical syndromes induced by acute, severe hypertension include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moderate to severe hypertensive retinopathy</strong> − Moderate to severe hypertensive retinopathy, corresponding to grades III and IV hypertensive retinopathy, is characterized by retinal hemorrhages, exudates, and papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>) [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/3859.html" rel="external">"Ocular effects of hypertension", section on 'Ocular diseases directly related to hypertension'</a>.)</p><p></p><p class="bulletIndent1">Severe hypertensive retinopathy was formerly called "malignant hypertension," a term that clinicians should avoid (although it is used for administrative purposes in the United States). Moderate hypertensive retinopathy was often referred to as "accelerated hypertension," but this term should likewise be avoided. Patients with moderate to severe hypertensive retinopathy frequently have acute hypertensive nephrosclerosis (formerly called "malignant nephrosclerosis"), although kidney biopsies are seldom performed.</p><p></p><p class="bulletIndent1">Historically, papilledema was the hallmark of a more advanced condition (ie, "malignant hypertension") associated with a higher mortality (akin to having a malignancy). However, the advent of effective antihypertensive drug therapy has improved the prognosis and patients with severe hypertensive retinopathy have similar outcomes to those with moderate hypertensive retinopathy [<a href="#rid7">7</a>]. Thus, acute treatment of such patients is the same whether or not papilledema is present.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertensive encephalopathy</strong> − Hypertensive encephalopathy refers to the presence of signs and/or symptoms of cerebral edema caused by severe and/or sudden rises in BP. It is primarily a diagnosis of exclusion after other causes of central nervous system dysfunction are ruled out, and it characteristically responds dramatically to acute lowering of the mean arterial pressure, sometimes by as little as 10 to 15 percent. (See  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults", section on 'Neurologic emergencies'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF VASCULAR INJURY</span><span class="headingEndMark"> — </span>With mild to moderate elevations in blood pressure (BP), the initial response is arterial and arteriolar vasoconstriction. This autoregulatory process both maintains tissue perfusion at a relatively constant level and prevents the increase in pressure from being transmitted to the smaller, more distal vessels [<a href="#rid8">8</a>].</p><p>With increasingly severe hypertension, however, autoregulation eventually fails  (<a class="graphic graphic_figure graphicRef57676" href="/z/d/graphic/57676.html" rel="external">figure 1</a>) [<a href="#rid8">8</a>]. The ensuing rise in pressure in the arterioles and capillaries leads to acute damage to the vascular wall. Disruption of the vascular endothelium then allows plasma constituents (including fibrinoid material) to enter the vascular wall, thereby narrowing or obliterating the vascular lumen. Within the brain, the breakthrough vasodilation from failure of autoregulation leads to the development of cerebral edema and the clinical picture of hypertensive encephalopathy [<a href="#rid8">8</a>].</p><p>The level at which fibrinoid necrosis occurs depends upon the chronic baseline BP (prior to the substantial increase in BP). Patients with chronic hypertension have arteriolar hypertrophy that minimizes the transmission of pressure to the capillary circulation. Grades III and IV hypertensive retinopathy are often associated with diastolic pressures above 120 mmHg. By comparison, hypertensive encephalopathy can be seen at diastolic pressures as low as 100 mmHg in previously normotensive patients with acute hypertension due to preeclampsia or acute glomerulonephritis; patients in whom autoregulation is impaired also may develop hypertensive injury at relatively mild degrees of hypertension [<a href="#rid8">8</a>].</p><p>In addition to protecting tissues against the effects of severe hypertension, autoregulation also maintains tissue perfusion during the treatment of hypertension via arterial and arteriolar vasodilation. Since flow is equal to pressure divided by resistance, parallel reductions in both parameters allow sufficient blood flow to be maintained. However, an excessive hypotensive response <strong>below</strong> the autoregulatory range can lead to ischemic symptoms  (<a class="graphic graphic_figure graphicRef57676" href="/z/d/graphic/57676.html" rel="external">figure 1</a>). The arteriolar hypertrophy induced by chronic hypertension means that hypoperfusion will occur at a higher BP than in normotensive subjects [<a href="#rid8">8</a>].</p><p>It has been suggested that factors other than the level of BP, particularly activation of the renin-angiotensin system, may contribute to the development of fibrinoid necrosis. Plasma renin activity is often increased in patients with grades III and IV hypertensive retinopathy, potentially mediated by both an initial natriuresis induced by the high pressure and renal vascular injury. The importance of the renin-angiotensin system in the vascular injury of severe hypertension has been demonstrated in transgenic rats [<a href="#rid9">9</a>]. In this study, rats prone to severe hypertension were treated with low-dose <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a> (5 mg/day) or no therapy. Ramipril significantly reduced the frequency of arteriolar fibrinoid necrosis, despite having no significant effect on BP, suggesting a role for the renin-angiotensin system independent of BP.</p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span><span class="headingEndMark"> — </span>Moderate to severe hypertensive retinopathy and hypertensive encephalopathy most often occur in patients with longstanding, uncontrolled hypertension, many of whom have discontinued antihypertensive drug therapy [<a href="#rid10">10</a>]. Secondary hypertension, especially renovascular hypertension, is more common in patients with advanced hypertensive retinopathy than in hypertensive individuals without such funduscopic findings [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H2194581703"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>In addition to marked elevation in blood pressure (BP), the major clinical manifestations of hypertensive retinopathy and encephalopathy include the following [<a href="#rid3">3,4,12,13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with moderate to severe hypertensive retinopathy do not usually have visual symptoms, although 5 to 10 percent may have visual complaints. However, the ophthalmologic examination can reveal retinal hemorrhages and/or exudates (representing both ischemic damage and leakage of blood and plasma from affected vessels) and papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>). Yet few non-ophthalmologists can distinguish moderate from severe retinopathy, and the value of funduscopy in hypertensive patients is unclear [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/3859.html" rel="external">"Ocular effects of hypertension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic symptoms are frequent in patients with severe hypertension [<a href="#rid15">15</a>]. Hypertensive encephalopathy, which is related to cerebral edema, is characterized by the <strong>insidious</strong> onset of headache, nausea, and vomiting, followed by nonlocalizing neurologic symptoms such as restlessness, confusion, and, if the hypertension is not treated, seizures and coma [<a href="#rid12">12</a>]. In contrast, patients with ischemic stroke or intracerebral hemorrhage typically present with abrupt and focal neurologic symptoms. However, such patients may occasionally have insidious and generalized neurologic symptoms and, because the treatment of ischemic stroke and intracerebral hemorrhage differs significantly from the treatment of hypertensive encephalopathy, diagnostic brain imaging is critical to distinguish the cause of neurologic symptoms. (See <a class="local">'Diagnosis'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with severe hypertensive retinopathy and/or hypertensive encephalopathy often have acute hypertensive nephrosclerosis, leading to acute kidney injury, hematuria, and proteinuria. Acute hypertensive nephrosclerosis is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults", section on 'Kidney emergencies'</a>.)</p><p></p><p class="headingAnchor" id="H2194581737"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Hypertensive retinopathy is diagnosed by ophthalmologic examination of the eyes, with identification of retinal hemorrhages, exudates, and/or papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3859.html" rel="external">"Ocular effects of hypertension"</a>.)</p><p>Hypertensive encephalopathy is a diagnosis of exclusion, confirmed retrospectively when neurologic symptoms improve after the BP is lowered into (but not beyond) the autoregulatory range  (<a class="graphic graphic_figure graphicRef57676" href="/z/d/graphic/57676.html" rel="external">figure 1</a>). However, cerebral imaging, particularly magnetic resonance imaging (MRI) with T<sub>2</sub>-weighted images, may reveal edema of the white matter of the parieto-occipital regions, a finding consistent with hypertensive encephalopathy that is termed reversible posterior leukoencephalopathy syndrome [<a href="#rid16">16</a>]. When the MRI reveals primarily pontine abnormalities, the condition has been called hypertensive brainstem encephalopathy [<a href="#rid17">17,18</a>]. (See  <a class="medical medical_review" href="/z/d/html/4835.html" rel="external">"Reversible posterior leukoencephalopathy syndrome"</a>.)</p><p>As noted above, ischemic stroke and intracerebral hemorrhage should usually be excluded in patients with severe hypertension and neurologic symptoms since treatment of these conditions differs from the treatment of hypertensive encephalopathy. Thus, in the presence of neurologic symptoms such as headache, nausea, and vomiting, followed by nonlocalizing symptoms such as restlessness, confusion, seizures, or coma, a computerized tomography (CT) or MRI scan of the brain should be obtained to exclude an acute ischemic stroke or hemorrhage, which are not routinely (or primarily) treated by reducing BP [<a href="#rid19">19</a>]. (See  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1126.html" rel="external">"Initial assessment and management of acute stroke", section on 'Blood pressure management'</a> and  <a class="medical medical_review" href="/z/d/html/1084.html" rel="external">"Spontaneous intracerebral hemorrhage: Acute treatment and prognosis", section on 'Blood pressure management'</a> and  <a class="medical medical_review" href="/z/d/html/1127.html" rel="external">"Aneurysmal subarachnoid hemorrhage: Treatment and prognosis", section on 'Blood pressure control'</a>.)</p><p class="headingAnchor" id="H2194582208"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H6"><span class="h2">Goal of therapy</span><span class="headingEndMark"> — </span>The initial aim of treatment in patients with moderate to severe hypertensive retinopathy and/or hypertensive encephalopathy is to rapidly lower the mean arterial pressure by approximately 10 to 15 percent in the first hour, and by no more than 25 percent compared with baseline by the end of the first day of treatment [<a href="#rid12">12,13</a>]. This level of blood pressure (BP) control will allow gradual healing of the necrotizing vascular lesions. More aggressive hypotensive therapy is both unnecessary and may reduce BP below the autoregulatory range, possibly leading to ischemic events (such as stroke or myocardial infarction) [<a href="#rid20">20,21</a>]. (See  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults", section on 'Neurologic emergencies'</a>.)</p><p>Once BP is controlled, the patient should be switched to oral therapy, with the systolic pressure being gradually reduced to &lt;130 mmHg and the diastolic pressure being gradually reduced to &lt;80 mmHg over two to three months. The initial reduction in BP is often associated with a modest worsening of kidney function; this change, however, is typically transient as the vascular disease tends to resolve and kidney perfusion improves over one to three months [<a href="#rid22">22</a>], even among patients treated with angiotensin-converting enzyme (ACE) inhibitors, renin inhibitors, or angiotensin II receptor blockers (ARBs) [<a href="#rid23">23</a>]. Antihypertensive therapy should not be withheld in this setting unless there has been an excessive reduction in pressure. (See  <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">"Evaluation and treatment of hypertensive emergencies in adults", section on 'Kidney emergencies'</a>.)</p><p>However, a change in medication may be required if the decline in kidney function only occurs after initiation of therapy with an ACE inhibitor, renin inhibitor, or ARB, which can interfere with renal autoregulation and produce acute kidney injury in patients with bilateral renal artery stenosis. (See  <a class="medical medical_review" href="/z/d/html/3873.html" rel="external">"Renal effects of ACE inhibitors in hypertension"</a>.)</p><p class="headingAnchor" id="H2194582302"><span class="h2">Choice of antihypertensive drug</span><span class="headingEndMark"> — </span>Initial treatment of marked hypertension-associated moderate (ie, grade III, hemorrhages or exudates) to severe (ie, grade IV, papilledema) hypertensive retinopathy and/or hypertensive encephalopathy usually includes parenteral antihypertensive drug therapy administered in an intensive care unit. (See <a class="local">'Parenteral antihypertensive therapy'</a> below.)</p><p>After a suitable period (often 8 to 24 hours) of BP control at target in the intensive care unit, oral medications may be started and the initial intravenous therapy is tapered and discontinued.</p><p>In settings where parenteral antihypertensive drugs are unavailable, rapidly acting oral agents (such as sublingual <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a>) may be used, although such medications may occasionally cause ischemic symptoms due to an unpredictable, excessive, and uncontrolled hypotensive response. (See <a class="local">'Oral alternatives'</a> below.)</p><p class="headingAnchor" id="H2268069224"><span class="h3">Parenteral antihypertensive therapy</span><span class="headingEndMark"> — </span>The parenteral antihypertensive agents most often used in the initial treatment of moderate to severe hypertensive retinopathy and/or hypertensive encephalopathy are briefly listed below [<a href="#rid12">12,13</a>]. A more detailed discussion about the pharmacology, dosing, and adverse effects of these agents is provided elsewhere  (<a class="graphic graphic_table graphicRef64066" href="/z/d/graphic/64066.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8911" href="/z/d/drug information/8911.html" rel="external">Clevidipine</a> – A short-acting dihydropyridine calcium channel blocker. It reduces BP without affecting cardiac filling pressures or causing reflex tachycardia. The initial dose is 1 mg/hour and the usual maximum dose is 21 mg/hour. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Clevidipine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9697" href="/z/d/drug information/9697.html" rel="external">Nicardipine</a> – A dihydropyridine calcium channel blocker with arteriolar dilator effect, given as an intravenous infusion. The initial dose is 5 mg/hour and the usual maximum dose is 15 mg/hour. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Nicardipine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8629" href="/z/d/drug information/8629.html" rel="external">Fenoldopam</a> – A peripheral dopamine-1 receptor agonist, given as an intravenous infusion. The initial dose is 0.1 mcg/kg per min and the dose is titrated at 15-minute intervals, depending upon BP response. Fenoldopam may be particularly beneficial in patients with kidney impairment. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Fenoldopam'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sodium <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">nitroprusside</a> – An arteriolar and venous dilator, given as an intravenous infusion. The initial dose is 0.25 to 0.5 mcg/kg per min and the usual maximum dose is 8 to 10 mcg/kg per min. The potential for cyanide and thiocyanate toxicity limits the prolonged use of nitroprusside, particularly in patients with acute or chronic kidney disease. (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Nitroprusside'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9540" href="/z/d/drug information/9540.html" rel="external">Labetalol</a> – An alpha and beta adrenergic blocker, given as an intravenous bolus or infusion. A 20 mg bolus is usually given initially, followed by 20 to 80 mg intravenously every 10 minutes to a total dose of 300 mg. Labetalol can also be given as a continuous infusion at 0.5 to 2 mg/min. Labetalol should not be used without prior adequate alpha blockade in patients with hyperadrenergic states (eg, cocaine-induced hypertension). (See  <a class="medical medical_review" href="/z/d/html/3840.html" rel="external">"Drugs used for the treatment of hypertensive emergencies", section on 'Labetalol'</a>.)</p><p></p><p class="headingAnchor" id="H2194582325"><span class="h3">Oral alternatives</span><span class="headingEndMark"> — </span>The use of oral antihypertensive agents as therapy for hypertensive emergencies is limited by slower onset of action and the inability to control both the rapidity and degree of BP reduction. However, such therapy may be useful in resource-limited settings when access to parenteral antihypertensive medications is lacking.</p><p>Rapid, unpredictable, and often substantial BP lowering can occur after either sublingual <a class="drug drug_general" data-topicid="9196" href="/z/d/drug information/9196.html" rel="external">captopril</a> (25 mg, single dose) or <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">nifedipine</a> (10 mg, single dose) [<a href="#rid24">24</a>]. Because sublingual nifedipine is minimally absorbed, swallowing nifedipine liquid (from a punctured capsule) is even faster, and perhaps even more dangerous.</p><p>The major risk of any oral agent used for hypertensive emergencies is ischemic symptoms (eg, angina pectoris, myocardial infarction, or stroke) due to an excessive and uncontrolled hypotensive response [<a href="#rid25">25</a>], usually due to lowering of BP to below the autoregulatory threshold. Thus, the use of oral agents should generally be <strong>avoided</strong> in the treatment of hypertensive emergencies if parenteral drugs are available  (<a class="graphic graphic_table graphicRef64066" href="/z/d/graphic/64066.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H7"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Even with effective antihypertensive therapy, most patients who have had moderate to severe hypertensive retinopathy and/or hypertensive encephalopathy have chronic and acute vascular damage and are at increased risk for coronary, cerebrovascular, and kidney disease. The magnitude of this problem was illustrated in a retrospective study that evaluated the kidney outcomes of 169 patients with grade III or IV hypertensive retinopathy [<a href="#rid26">26</a>]. Despite adequate antihypertensive therapy, progressive kidney function impairment occurred in 57 percent of patients after a mean follow-up of 53 months.</p><p>However, overall survival has improved markedly with the availability of antihypertensive medications. Historically, without therapy, one-year survival was only 10 to 20 percent [<a href="#rid27">27</a>]. With effective acute and chronic antihypertensive therapy, five-year survival rates of more than 70 percent are typical [<a href="#rid12">12,13</a>], with some studies reporting 90 percent survival at 40 to 52 months [<a href="#rid28">28</a>]. Patients with higher stages of chronic kidney disease tend to have a lower survival rate [<a href="#rid26">26,29</a>].</p><p class="headingAnchor" id="H1691108139"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109601.html" rel="external">"Society guideline links: Hypertension in adults"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/17188.html" rel="external">"Patient education: High blood pressure emergencies (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/4416.html" rel="external">"Patient education: High blood pressure in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4424.html" rel="external">"Patient education: High blood pressure treatment in adults (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/4415.html" rel="external">"Patient education: High blood pressure, diet, and weight (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19451673"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe (grades III and IV) hypertensive retinopathy is characterized by retinal hemorrhages, exudates, and papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>). (See <a class="local">'Definitions and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertensive encephalopathy refers to the presence of signs and/or symptoms of cerebral edema caused by a severe and/or sudden rise in blood pressure (BP). It is primarily a diagnosis of exclusion, after other causes of central nervous system dysfunction are ruled out, and it characteristically responds dramatically to acute lowering of the mean arterial pressure, sometimes by as little as 10 to 15 percent. (See <a class="local">'Definitions and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Moderate to severe hypertensive retinopathy and hypertensive encephalopathy most often occur in patients with longstanding, uncontrolled hypertension, many of whom have recently discontinued antihypertensive drug therapy. (See <a class="local">'Clinical manifestations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to marked elevation in BP, the major clinical manifestations include the following (see <a class="local">'Clinical manifestations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with moderate to severe hypertensive retinopathy do not usually have visual symptoms, but the ophthalmologic examination can reveal retinal hemorrhages and/or exudates (representing both ischemic damage and leakage of blood and plasma from affected vessels) and papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertensive encephalopathy, which is related to cerebral edema, is characterized by the <strong>insidious</strong> onset of headache, nausea, and vomiting, followed by nonlocalizing neurologic symptoms such as restlessness, confusion, and, if the hypertension is not treated, seizures and coma.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with severe hypertensive retinopathy and/or hypertensive encephalopathy often have acute hypertensive nephrosclerosis, leading to acute kidney injury, hematuria, and proteinuria.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertensive retinopathy is diagnosed by ophthalmologic examination of the eyes, with identification of retinal hemorrhages, exudates, and/or papilledema  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/z/d/graphic/104437.html" rel="external">image 1</a>). (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypertensive encephalopathy is a diagnosis of exclusion, confirmed retrospectively when neurologic symptoms improve after the BP is lowered into the autoregulatory range. However, cerebral imaging, particularly magnetic resonance imaging (MRI) with T<sub>2</sub>-weighted images, may reveal edema of the white matter of the parieto-occipital regions, a finding consistent with hypertensive encephalopathy that is termed "reversible posterior leukoencephalopathy syndrome." When the MRI reveals primarily pontine abnormalities, the condition has been called "hypertensive brainstem encephalopathy." Ischemic stroke and intracerebral hemorrhage should be excluded in patients with severe hypertension and neurologic symptoms since treatment of these conditions differs from the treatment of hypertensive encephalopathy. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The initial aim of treatment in patients with moderate to severe hypertensive retinopathy and/or hypertensive encephalopathy is to rapidly lower the mean arterial pressure by approximately 10 to 15 percent in the first hour, and by no more than 25 percent compared with baseline by the end of the first day of treatment. (See <a class="local">'Goal of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial treatment of marked hypertension-associated moderate to severe hypertensive retinopathy and/or hypertensive encephalopathy usually includes parenteral antihypertensive drug therapy administered in an intensive/critical care unit. After a suitable period (often 8 to 24 hours) of BP control at target in the intensive care unit, oral medications are usually given and the initial intravenous therapy is tapered and discontinued. (See <a class="local">'Choice of antihypertensive drug'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:e13.</a></li><li><a class="nounderline abstract_t">Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131:1949.</a></li><li><a class="nounderline abstract_t">Cremer A, Amraoui F, Lip GY, et al. From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 2016; 30:463.</a></li><li><a class="nounderline abstract_t">Adebayo O, Rogers RL. Hypertensive Emergencies in the Emergency Department. Emerg Med Clin North Am 2015; 33:539.</a></li><li><a class="nounderline abstract_t">Williams B, Mancia G, Spiering W, et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2018; 36:2284.</a></li><li><a class="nounderline abstract_t">Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351:2310.</a></li><li><a class="nounderline abstract_t">Ahmed ME, Walker JM, Beevers DG, Beevers M. Lack of difference between malignant and accelerated hypertension. Br Med J (Clin Res Ed) 1986; 292:235.</a></li><li><a class="nounderline abstract_t">Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 1989; 2:486.</a></li><li><a class="nounderline abstract_t">Montgomery HE, Kiernan LA, Whitworth CE, et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998; 16:635.</a></li><li><a class="nounderline abstract_t">Patel R, Ansari A, Grim CE, Hidaka M. Prognosis and predisposing factors for essential malignant hypertension in predominantly black patients. Am J Cardiol 1990; 66:868.</a></li><li><a class="nounderline abstract_t">Davis BA, Crook JE, Vestal RE, Oates JA. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. N Engl J Med 1979; 301:1273.</a></li><li><a class="nounderline abstract_t">Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.</a></li><li class="breakAll">Kaplan NM, Victor RG. Hypertensive emergencies. In: Kaplan's Clinical Hypertension, 11th Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2015. p.263.</li><li><a class="nounderline abstract_t">van den Born BJ, Hulsman CA, Hoekstra JB, et al. Value of routine funduscopy in patients with hypertension: systematic review. BMJ 2005; 331:73.</a></li><li><a class="nounderline abstract_t">Phillips SJ, Whisnant JP. Hypertension and the brain. The National High Blood Pressure Education Program. Arch Intern Med 1992; 152:938.</a></li><li><a class="nounderline abstract_t">Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494.</a></li><li><a class="nounderline abstract_t">Kitaguchi H, Tomimoto H, Miki Y, et al. A brainstem variant of reversible posterior leukoencephalopathy syndrome. Neuroradiology 2005; 47:652.</a></li><li><a class="nounderline abstract_t">Meylaerts L, Ooms V, Lyra S, et al. Hypertensive brain stem encephalopathy in a patient with chronic renal failure. Clin Nephrol 2006; 65:138.</a></li><li><a class="nounderline abstract_t">Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741.</a></li><li><a class="nounderline abstract_t">Ledingham JG, Rajagopalan B. Cerebral complications in the treatment of accelerated hypertension. Q J Med 1979; 48:25.</a></li><li><a class="nounderline abstract_t">Haas DC, Streeten DH, Kim RC, et al. Death from cerebral hypoperfusion during nitroprusside treatment of acute angiotensin-dependent hypertension. Am J Med 1983; 75:1071.</a></li><li><a class="nounderline abstract_t">Woods JW, Blythe WB. Management of malignant hypertension complicated by renal insufficiency. N Engl J Med 1967; 277:57.</a></li><li><a class="nounderline abstract_t">Mourad G, Mimran A, Mion CM. Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril. Nephron 1985; 41:166.</a></li><li><a class="nounderline abstract_t">Angeli P, Chiesa M, Caregaro L, et al. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial. Arch Intern Med 1991; 151:678.</a></li><li><a class="nounderline abstract_t">Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328.</a></li><li><a class="nounderline abstract_t">Lip GY, Beevers M, Beevers DG. Does renal function improve after diagnosis of malignant phase hypertension? J Hypertens 1997; 15:1309.</a></li><li><a class="nounderline abstract_t">Dustan HP, Schneckloth RE, Corcoran AC, Page IH. The effectiveness of long-term treatment of malignant hypertension. Circulation 1958; 18:644.</a></li><li><a class="nounderline abstract_t">van den Born BJ, Honnebier UP, Koopmans RP, van Montfrans GA. Microangiopathic hemolysis and renal failure in malignant hypertension. Hypertension 2005; 45:246.</a></li><li><a class="nounderline abstract_t">González R, Morales E, Segura J, et al. Long-term renal survival in malignant hypertension. Nephrol Dial Transplant 2010; 25:3266.</a></li></ol></div><div id="topicVersionRevision">Topic 3833 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133356" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565029" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hypertensive crises: challenges and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26582411" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26226865" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypertensive Emergencies in the Emergency Department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30379783" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15564546" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hypertensive retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3081084" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lack of difference between malignant and accelerated hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2757806" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cerebral blood flow and its pathophysiology in hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9797175" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2220590" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognosis and predisposing factors for essential malignant hypertension in predominantly black patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/503132" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972386" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10972386" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Hypertensive emergencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002881" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Value of routine funduscopy in patients with hypertension: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580719" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Hypertension and the brain. The National High Blood Pressure Education Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559202" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A reversible posterior leukoencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947925" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A brainstem variant of reversible posterior leukoencephalopathy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509465" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Hypertensive brain stem encephalopathy in a patient with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21316752" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/482589" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cerebral complications in the treatment of accelerated hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650540" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Death from cerebral hypoperfusion during nitroprusside treatment of acute angiotensin-dependent hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6027134" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Management of malignant hypertension complicated by renal insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3900778" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Recovery of renal function in patients with accelerated malignant nephrosclerosis on maintenance dialysis with management of blood pressure by captopril.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2012448" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies. A randomized, single-blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8861992" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9383181" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Does renal function improve after diagnosis of malignant phase hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13573582" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effectiveness of long-term treatment of malignant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15596574" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Microangiopathic hemolysis and renal failure in malignant hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299339" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Long-term renal survival in malignant hypertension.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
